Modern aspects of medicinal therapy of patients with prostate hyperplasia using A1-adreno blockers

Benign prostatic hyperplasia (prostate adenoma, BPH) is one of the most common diseases of elderly men. The incidence increases with age. If at autopsy at the age of 41-50 years, prostate adenoma is found in about 20% of cases, then at 51-60 years - already in 50%, and at 80 years and older - in 90%. RH symptoms requiring treatment occur in 60% of men over 50 years of age [2]. The results of epidemiological studies indicate a clear trend towards an aging population. Today, the average life expectancy of a man in Europe and North America is 72 years and continues to grow [4]. The growth dynamics is such that from 1980 to 2050. the population over 65 should double to 15% of the entire human population. As a result, an increase in the number of potential patients suffering from prostatic hyperplasia can be expected. In this regard, the diagnosis and treatment of BPH is not only a serious medical problem, but also a great social problem.